Start
•
Completion

Evaluation of Psilocybin (TRP-8802) to Decrease Hyperphagia

Not yet recruitingRegisteredCTG

This is a single-center Phase IIa open-label study to assess the efficacy and safety of a dose of psilocybin in subjects with hyperphagia resulting in overeating during both dosing sessions

Details

Single-centre, open-label Phase IIa study of TRP-8802 (psilocybin) in adults with binge eating disorder to assess safety and feasibility with a single 25 mg oral dose paired with preparatory and integration psychotherapy.

Participants undergo screening, preparatory therapy (6–8 hours), a monitored dosing session, and integration plus follow-up to 12 weeks post-dose (Week 14); total participation approximately 5 months.

Topics:Eating Disorders

Registry

Registry linkNCT05035927